Skip to content

Study · Not a test of the peptide alone · 2001

1 result

Regulation of proliferation of prostate epithelial cells by 1,25-dihydroxyvitamin D3 is accompanied by an increase in insulin-like growth factor binding protein-3.

Sprenger CC, Peterson A, Lance R, Ware JL, Drivdahl RH, Plymate SR

The Journal of endocrinology1 Sept 2001Cited by 25 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking IGF-1 DES (des(1-3)IGF-I).

  1. 01LabNot a test of IGF-1 DES (des(1-3)IGF-I) aloneIn vitro (cells)Activity measurement

    In benign prostate epithelial cell systems tested with IGF-I or des(1‑3)IGF-I, 1,25-(OH)2D3 inhibited IGF-induced proliferation.

    In plain wordsIn cells tested with IGF-I or des(1‑3)IGF-I, vitamin D reduced IGF-stimulated growth compared with stimulation alone.

    Outcome
    DecreaseVitamin D inhibition of IGF-induced proliferation
    Study

    humann: not reported in source

    Benign human prostate epithelial cells and P153 cells
    Comparator
    IGF stimulation without 1,25-(OH)2D3
    Outcome group
    Receptor activity and mechanism · Reproductive and sexual health

    Source sentences

    Summary
    Furthermore, 1,25-(OH)2D3 inhibited IGF-induced proliferation
    2 context sentences
    Summary · context
    Two cell systems were used in this study: (1) primary cultures of benign human prostate epithelial cells (PECs) and (2) an SV40-T immortalized prostate epithelial cell line (P153) that is non-tumorigenic.
    Summary · context
    1,25-(OH)2D3 was added to parallel sets of PECs and P153 cells in addition to the presence or absence of IGF-I or des(1-3)IGF-I.

    In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 13:52 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.